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ABSTRACT
The small airway disease in asthma is characterized by
airway wall thickening associated with eosinophilic
inflammation and hypervascularity. In our study,
predicted forced expiratory volume in 1 s (% FEV1)
correlated with the vascularity in the inner layers of
large airways but not for small airways. High-
resolution computed tomography (CT) scans of
0.5 mm collimation during acute mild exacerbations
revealed mucus plugging, air-space nodules and
ground-glass opacities. Mean lung density on CT
in  acute exacerbations was significantly increased
compared with that in remission. These results suggest
that the involvement of the small airways and lung
parenchyma would be increased during exacerba-
tions. Pathologically, eosinophils were significantly
reduced by treatment with chlorofluorocarbon–
beclomethasone dipropionate (BDP) in the large air-
ways, but not in the small airways. New fine-particle
inhaled corticosteroids (ICS), such as hydrofluoroalkane-
BDP, can reach the small airways and lung paren-
chyma in asthmatic patients. From the results of peak
inspiratory flow (PIF) through each dry powder inhaler
in Japanese people, measurement of PIF should be
recommended before the use of dry powder inhaler. In
the present review, we address small airway disease in
asthmatic patients using pathological and radiological
methods and discuss the critical problems of current
ICS therapy.
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puted tomography, inhaled corticosteroid, small airway.
INTRODUCTION
Asthma is a chronic inflammatory disease affecting the
whole bronchial tree, from large to small airways.1,2
However, information about the small airways and lung
parenchyma in asthmatic patients and comparison of
bronchial remodeling and inflammation between central
and peripheral airways is lacking.3 The contribution
of small airway involvement to acute exacerbations of
asthma also remains unknown. High-resolution com-
puted tomography (HRCT) has been useful for assessing
structural changes in the asthmatic lung and permits
investigation of the relationship between airway wall
thickening and clinical parameters. Multidetector-row
CT (MDCT) is now widely available and can scan the
whole lung within a very short time compared with
previous HRCT, enabling us to evaluate acute exacerba-
tions with mild respiratory failure.
Inhaled corticosteroid (ICS) is a well-established anti-
inflammatory therapy for asthma and steroid receptors
are located throughout the bronchial tree.4 In general,
the smaller particles can reach the more peripheral
airways but, for an optimal therapeutic response to
ICS, the inhaled particles should reach both large
and small airways. Recently, a solution steroid aerosol,
hydrofluoroalkane–beclomethasone dipropionate (HFA-
BDP), was developed with a mass median aerodynamic
diameter (MMAD) of 1.1 µm,5 raising the possibility
that  this extra-fine ICS may be more effective than
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conventional chlorofluorocarbon (CFC)-BDP, with an
MMAD of 3.5 µm, in improving function in the small
airways of asthmatic patients through more effective
suppression of peripheral airway inflammation. We also
address the problems regarding inhalation technique in
patients with asthma and chronic obstructive pulmonary
disease (COPD) and the significance of particle size of
dry powder inhaler (DPI) and pressurized metered-dose
inhaler (pMDI) of ICS. In the present review, we address
small airway disease in asthmatic patients using patho-
logical and radiological methods and discuss the critical
problems of current ICS therapy.
PATHOLOGICAL APPROACH
Bronchial wall inflammation
Many investigators have reported inflammatory changes
in the small airways in subjects with fatal and mild
asthma using lung specimens obtained by operation.
Saetta et al.6 found evidence of increased mucus plug-
ging, airway smooth muscle thickening and infiltration of
inflammatory cells, including eosinophils, in the small
airways in fatal asthma. Kuwano et al.7 and Carroll
et al.3,8 reported that remodeling also occurred in
mild asthma. Hamid et al.2 observed that inflammatory
changes were more severe in small airways than in large
airways of asthmatic patients who had undergone lung
resection for tumor, whereas Kraft et al.9 reported that
eosinophilic inflammation was greater in peripheral
tissue than in the large bronchi in the early morning
hours.
Bronchial wall angiogenesis
Angiogenesis is characteristic of airway remodeling in
asthma, but there have been few reports as to bronchial
wall hypervascularity in the small airways. We found that
the number of vessels and percent vascularity were
increased in both large and small airways in patients
with asthma compared with control subjects.10 Because
previous in vivo quantitative studies used biopsy speci-
mens obtained by fiberoptic bronchoscopy, the observa-
tions were limited to the large airways, whereas our data
extend the finding of increased vascularity to small
airways. Li et al.11 did not find any relationship between
clinical parameters and airway vascularity in patients
with mild and moderate asthma, although Salvato12 and
Vrugt et al.13 showed that subjects with severe asthma
had more vessels compared with mild to moderate
asthmatics. In contrast, vascularity is more prominent in
the inner area,10 suggesting that airway edema due to
plasma leakage from mucosal capillary vessels may
increase the narrowing of the bronchial lumen and
increase airway resistance. Our study showed that
percentage forced expiratory volume in 1s (%FEV1)
correlated with vascularity in the inner layer of the large
airways, but not in the small airways.10 These results
suggest that hypervascularity of the inner layer of large
airways may contribute not only to disease severity, but
also to airflow limitation in asthmatic patients.
RADIOLOGICAL APPROACH
High-resolution CT appearance at asthma 
exacerbation
High-resolution CT is one of the most useful tools for
imaging the small airways and the direct signs are the
result of changes in the airway wall or lumen. Teel
et al.14 summarized small airway abnormalities as tubu-
lar, nodular or branching linear structures on HRCT
scans and described indirect signs of small airway
disease resulting from changes in the lung parenchyma
distal to the diseased small airway due to air trapping,
subsegmental atelectasis, centrilobular emphysema and
air-space nodules. Niimi et al.15 reported that airway
wall thickening measured by CT appeared in all degrees
of asthma disease and suggested its magnitude may
relate to the duration and degree of airflow limitation.
To evaluate airway remodeling of the large and small
airways and lung parenchyma during mild asthma
exacerbations, we assessed the CT findings of the right
upper lobe taken at 0.5 mm intervals and 0.5 mm
colimmation using MDCT. We examined the bronchial
wall of generations 2–5 in stable asthmatic patients and
patients with a mild exacerbation.16 We found that an
increase of wall area of generation 4 bronchus was most
responsible for airflow limitation (%FEV1) in stable
asthma, but found no relationship during mild exacer-
bation, suggesting that, during asthma exacerbation,
airflow may be restricted not only by large airway
narrowing and inflammation, but also by obstruction of
the small airway by mucus plugging. Actually, air-space
nodules and ground-glass opacities (GGO) appeared
on 0.5 mm colimation HRCT during mild exacerbation
(Fig. 1a,b). Micronodules also existed at the end of the
bronchus and continued to the pulmonary artery, find-
ings that appear in case of diffuse panbronchiolitis,
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which suggest that these nodules may reflect small
airway wall inflammation and mucus plugging.
Ground-glass opacities during asthma exacerbation
suggest eosinophil-dominant inflammation in the lung
parenchyma.
High-resolution CT lung density
The low-attenuation area (LAA) on CT has been shown
to represent macroscopic or microscopic emphysema in
patients with COPD and also has been used in the
detection of airspace enlargement in patients with
asthma. Mitsunobu et al.17 reported that LAA in non-
smoking asthmatics (11.0% ± 9.7) was significantly
increased compared with that in non-smoking controls
(3.6% ± 3.2) and mean lung density (MLD) in non-
smoking asthmatics (–845 ± 32 Hounsfield units (HU))
was significantly lower than that in non-smoking controls
(–818 ± 29 HU). Mitsunobu et al.17 also reported that
both MLD and LAA correlated with parameters of airflow
limitation and lung volume, but not with the lung transfer
factor in non-smoking asthmatic patients.18 We also
measured CT lung density using MDCT in patients with
stable asthma and with a mild exacerbation.19 In our
study, LAA in non-smoking asthma (10.3 ± 5.4%) was
increased, but not significantly, compared with non-
smoking controls (9.2 ± 4.2%) and MLD in non-smoking
asthma (–871 ± 31 HU) was higher, but not signifi-
cantly, compared with non-smoking controls (–861 ±
31 HU). The different results may be explained by the
selection of patients, because we excluded subjects with
emphysematous change, giant bulla or cystic lesions on
CT,19 but Mitsunobu et al.17,18 did not. We also found
that MLD in patients with mild exacerbations was signifi-
cantly higher than in patients with stable asthma,
whereas the LAA area in patients with mild exacerbation
was significantly decreased compared with that in
patients with stable asthma (S Sahara et al., unpubl.
obs., 2003). These results suggest that peripheral lung
lesions may develop during asthma exacerbations. There
has been no report about CT lung density during asthma
exacerbation, but Kraft et al.20 reported that lung biopsy
specimens at 04.00 h in patients with nocturnal asthma
demonstrated increased eosinophil infiltration into the
lung parenchyma. We speculate that lung parenchyma
lesions may be increased during asthma exacerbations.
The difference in peripheral lung density between
inspiratory and expiratory CT is also useful for the detec-
tion of air trapping by small airway narrowing. Goldin
et al.21 evaluated the efficacy of inhaled broncho-
constrictor (methacholine) and bronchodilator (albuterol)
by assessing expiratory CT (at the residual volume level).
They observed that the marked increase in LAA due to air
trapping by inhalation of methacholine returned to base-
line levels after inhalation of albuterol, suggesting that
LAA on expiratory CT reflects prompt changes of small
airway obstruction in asthmatic patients.
LIMITATION OF ICS THERAPY
Lung deposition of ICS
Inhaled corticosteroids are powerful anti-inflammatory
drugs and, for optimal therapeutic response with ICS,
the inhaled particles should reach both the large and
small airways. Recently, a fine-particle ICS of HFA-BDP
has become available with an MMAD of 1.1 µm.5 Leach
et al.22 reported that lung deposition, using gamma
scintigraphy was greater with HFA-BDP (53%) compared
with CFC-BDP (4%) in nine healthy non-smoking
volunteers and that HFA-BDP was distributed diffusely
throughout the lungs, whereas deposition of CFC-BDP
was mainly in the large and intermediate airways. The
pattern of lung deposition showed that HFA-BDP was
spread diffusely through the lung airways, whereas CFC-
BDP was confined to the large airways with little in the
small airways. We evaluated lung specimens of mild and
moderate asthma obtained at operation due to a small
lung cancer10 and the number of eosinophils in the
bronchial wall was significantly reduced by CFC-BDP
400–600 µg/day in the large airways, but not in the
Fig. 1 High-resolution computed tomography of 0.5 mm
collimation on asthma exacerbation. Ground glass opacities
(a) and nodular opacities (arrows) connecting to the end of a
bronchiole (b) are shown.
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small airways (Fig. 2). Possibly, the particle size of CFC-
BDP (MMAD 3.5 µm) prevented it reaching to the small
airways.
Peak inspiratory flow in DPI
Three devices of DPI, namely Diskhaler®, Diskus®
(GlaxoSmithkline, Brentford, UK) and Turbuhaler®
(AstraZeneca, Lumd, Sweden), are currently available in
Japan. They are increasingly being used in preference to
Table 1 Patient characteristics
Asthma COPD
No. patients 223 43 
Sex (M/F) 90/133 38/5
Age (years) 53 ± 16 71 ± 8
PEF (L/min) 361 ± 121 225 ± 101
PIF (L/min) 230 ± 73 165 ± 65
Inhaled corticosteroids (no. patients)
CFC-BDP 95 5
DPI-FP (diskhaler) 106 10
None 22 28
Where appropriate, data are given as the mean ± SD.
COPD, chronic obstructive pulmonary disease; PEF, peak expiratory
flow; PIF, peak inspiratory flow; CFC, chlorofluorocarbon; BDP,
beclomethasone dipropionate; DPI, dry powder inhaler; FP, fluticasone.
Fig. 3 Correlation between peak expiratory flow (PEF) and
peak inspiratory flow (PIF) measured using In-Check® (Clement
Clarke, Harlow, Essex, UK) in patients with asthma (λ;
n = 223; r = 0.67; P < 0.0001) and chronic obstructive
pulmonary disease (COPD; ; n = 43; r = 0.69; P < 0.0001).
The PIF in COPD is relatively higher than that in asthma
compared with the value of PEF.
Fig. 4 Histograms of peak inspiratory flow (PIF) in 223
asthmatic patients determined using In-Check® (Clement Clarke,
Harlow, Essex, UK) through each adaptor: (a) Diskhaler®;
(b) Diskus®; (c) Turbuhaler® .
Fig. 2 Number of eosinophils at the inner layer of large
airways (inner diameter 2–5 mm) and small airways (inner
diameter < 2 mm) in lung specimens obtained by operation
due to a peripheral small malignant tumor. In the large
airways, the number of eosinophils in patients treated with
chlorofluorocarbon–beclomethasone dipropionate (CFC-BDP)
was significantly (P = 0.013) decreased compared with subjects
without CFC-BDP treatment; however, this sort of reduction in
eosinophil numbers was not seen in the small airways.
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the conventional aerosol pMDI, because patients find
them easier to use and, furthermore, they do not contain
CFC. However, a potentially serious disadvantage is that
their efficient use is dependent on the generation of an
adequate inspiratory flow. Although the effect of PIF on
drug delivery through the DPI inhalation device is well
known, there have been few studies using Diskhaler®,
Diskus® and Turbuhaler® in Japanese people.23 There-
fore, we evaluated peak expiratory flow (PEF) using a
Mini-Wright® peak expiratory flow meter (Clement
Clarke, Harlow, Essex, UK) and PIF using an In-Check®
peak inspiratory flow meter (Clement Clarke) in 266 out-
patients; 223 patients with asthma and 43 subjects with
COPD (Table 1). A significant correlation between PEF
and PIF existed in patients with asthma and those with
COPD, but PEF was extremely low compared with PIF
in subjects with COPD (Fig. 3). This fact showed that
expiratory airflow may be limited in patients with COPD,
but the limitation of inspiratory airflow was slight,
suggesting that COPD patients can use the DPI as well
as asthmatic patients. Next, PIF through Diskhaler®,
Diskus® or Turbuhaler® was measured at a maximal
forced inspiration using another In-check® attached to
each inhaler adaptor. Histograms of PIF for each device
adaptor in the 223 asthmatic patients are shown in
Fig. 4. For optimal lung deposition, patients with PIF
values of 60–90 L/min are recommended to use the
Diskhaler®, whereas those with PIF values of 30–90 L/
min are recommended to use the Diskus® or the
Turbuhaler®. In measuring PIF through the Diskhaler®,
28 asthmatic patients had a low PIF under 60 mL/min
and although these patients were almost all women, it
did not appear that the result was age dependent (age
range 25–76 years). It is suggested that PIF should be
measured before the use of DPI.
CONCLUSION
Newly refined morphometric and immunohisto-
chemical techniques have been used to detect asthma
inflammation in the small airways and these techno-
logical changes have had a profound clinical impact.
Now, it is understood that the eosinophilic infiltration
occurs throughout the asthmatic lung. The contribu-
tion of small airway inflammation to deficits in pulmo-
nary function has been clarified by HRCT imaging.
Current treatment with CFC-BDP by pMDI or DPI can
suppress the inflammation in the large airways but a
little in the small airways. In contrast, new formula-
tions of fine-particle ICS, such as HFA-BDP, can
penetrate into the small airways and lung parenchyma.
Their potential to treat inflammation at the level of the
small airway may lead to significant improvements in
asthma outcome.
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